title: [Fondaparinux treatment in heparin induced thrombocytopenia:a case report].
abstract: Heparin induced thrombocytopenia is a serious complication of heparin therapy that has a high levels of morbidity and mortality due to thrombotic complications. Heparin induced thrombocytopenia usually develops between days 5 and 14 (inclusive) following initiation of heparin. When heparin induced thrombocytopenia is suspected, heparin should be discontinued and treatment with a direct thrombin inhibitor should be initiated. Heparin induced thrombocytopenia occurs more frequently with unfractionated heparin than with low molecular weight heparin. In this manuscript, we presented a case diagnosis with heparin induced thrombocytopenia who was given low molecular weight heparin for prophylaxis. We tried to make an overview of new treatment choices along with current literature.
authors: Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. savoz@mynet.com
authors: Savaş
authors: S
authors: Ozsu
authors: Ahmet
authors: A
authors: Korkmaz
authors: Yilmaz
authors: Y
authors: Bülbül
authors: Funda
authors: F
authors: Oztuna
authors: Tevfik
authors: T
authors: Ozlü
mesh_terms: D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D000077425:Fondaparinux